heart failure
Novartis’ Entresto helps preserve kidney function in chronic heart failure patients
April 16, 2018Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma
Novartis has lifted the curtain on new data from a Phase 3 trial investigating the efficacy of Entresto (sacubitril/valsartan) in …
Teva spared payout to GSK over patent infringement dispute
March 29, 2018Sales and Marketing Coreg, GSK, GlaxoSmithKline, Teva, carvedilol, heart failure, pharma
Teva has been spared a sizeable payout to GlaxoSmithKline after a federal judge overturned a US jury verdict demanding that …
Battling misinformation on the world’s biggest killer
August 14, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing cardiovascular disease, cholesterol, healthcare, heart disease, heart failure, medicine, pharma, pharmaceutical
Simon Williams, Head of Communications and Policy at Heart UK, discusses the threat posed by cholesterol in the development of …
Heart failure market to quadruple in ten years to $16 billion
July 6, 2017Sales and Marketing GlobalData, Novartis, heart failure
New research from intelligence firm GlobalData has indicated that the market for heart failure drugs is forecast to expand by …
Novo Nordisk diabetes drug Victoza fails to reduce heart failure risk
August 5, 2016Medical Communications, Research and Development Eli Lily, Novo Nordisk, Victoza, diabetes, heart failure
Novo Nordisk’s diabetes drug Victoza (liraglutide), which was found to cut cardiovascular risks in sufferers of heart disease, has failed …
Novartis’ heart failure drug Entresto gets top US, EU recommendation
May 23, 2016Research and Development, Sales and Marketing Ernesto, Novartis, heart failure, regulation
Swiss drugmaker Novartis (VTX: NOVN) said its heart failure drug Entresto (sacubitril/ valsartan) has secured top recommendations in the US …
Cell Therapy signs £12.5 million licensing deal with Daiichi Sankyo for heart failure treatment
May 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Daiichi Sankyo, Deals, cell therapy, heart failure, licensing
UK-based Cell Therapy on Tuesday said it has signed a £12.5 million licensing deal with Japan’s Daiichi Sankyo (TYO: 4568) …
NICE gives green light to Novartis’s heart drug Entresto
April 27, 2016Research and Development, Sales and Marketing Entresto, NHS, NICE, Novartis, benefit, heart failure, patients
NICE has published final guidance recommending heart failure drug Entresto (sacubritil/valsartan). The drug, developed by Novartis, has performed well in …
Novartis’s heart failure drug given final recommendation by NICE
March 21, 2016Manufacturing and Production, Research and Development Entresto, NICE, Novartis, approval, draft, guidance, heart failure, heart failure drug
The National Institute for Health and Care Excellence (NICE) has issued its final guidance on Entresto (sacubritil/valsartan), a heart failure …
Novartis earns provisional NICE yes for Entresto
December 11, 2015Sales and Marketing Entresto, NICE, Novartis, chronic heart failure, heart failure
NICE has indicated it is likely to recommend Entresto, a novel drug manufactured by Novartis, as a treatment option for …
Novartis’ new heart failure medicine recommended for EU approval
September 25, 2015Medical Communications, Research and Development Entresto, Novartis, eams, heart failure
The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Novartis’s heart failure medication Entresto …
Novartis heart failure drug available via EAMS
September 3, 2015Sales and Marketing Early Access to Medicines Scheme, Entresto, LCZ696, MHRA, Novartis, eams, heart failure, sacubitril/valsartan
Novartis has won the investigational heart failure treatment LCZ696 (sacubitril valsartan) will be available in the UK under the Early …
Novartis wins US nod for new heart drug
July 8, 2015Research and Development, Sales and Marketing Entestro, FDA, LCZ696, Novartis, ejection fraction, heart failure, reduced ejection fraction, sacubitril
The FDA has given the green light to Novartis’ new heart failure drug, six weeks ahead of the scheduled date …
BMS enters gene therapy development deal
April 7, 2015Research and Development BMS, Bristol-Myers Squibb, R&D, cardiovascular disease, cvd, heart disease, heart failure, uniQure
Bristol-Myers Squibb (BMS) has signed a multi-million dollar agreement with Amsterdam-based gene therapy firm uniQure to boost research into new …
Novartis emphasises pharma growth
June 19, 2014Sales and Marketing Novartis, breezhaler, dermatology, heart failure, oncology, respiratory
Novartis is to grow its pharma business by focussing on five key areas and predicts that it will have 14 …
